More than 50% rise in chemotherapy demand by 2040
The researchers call for a significant expansion of the chemotherapy workforce to deliver optimal treatment by 2040
A new study predicts that between 2018 and 2040, the number of patients needing chemotherapy each year will rise from 9.8 million to 15 million globally – a 53% increase. The researchers call for a significant expansion of the chemotherapy workforce to deliver optimal treatment by 2040.
The modelling study by a team of researchers – including UNSW Medicine academics – was published in the prestigious The Lancet Oncology journal. It is the first study to estimate the scale of chemotherapy provision needed at national, regional, and global scales to respond to this situation.
Dr Brooke Wilson is a conjoint lecturer at UNSW and first author on the study. She says the rising global cancer burden is undoubtedly one of the major health crises of today. “Strategies are urgently needed to equip the global health workforce to enable safe treatment of current and future patients,” she says.
“Countries and institutions should use our data to estimate their future cancer physician workforce requirements and chemotherapy needs and plan national, regional, and global strategies to ensure all those who need it will have access to chemotherapy treatment.”